| Literature DB >> 22594580 |
Bong-Hyeon Kye1, Jun-Gi Kim, Hyeon-Min Cho, Jung Hwan Lee, Hyung-Jin Kim, Young-Jin Suh, Chung-Soo Chun.
Abstract
BACKGROUND: This retrospective study compared the clinicopathological results among three groups divided by time sequence to evaluate the impact of introducing laparoscopic surgery on long-term oncological outcomes for right-sided colon cancer.Entities:
Mesh:
Year: 2012 PMID: 22594580 PMCID: PMC3449202 DOI: 10.1186/1477-7819-10-89
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Figure 1 This graph shows the learning curve (LC) for laparoscopic right-sided colon cancer surgery using CUSUM analysis (target value = 0.009). The LCs of laparoscopic right-sided colectomy in all TNM stage had been overcome after the 18th laparoscopic right-sided colectomy.
Overview of clinical data in 200 patients who underwent right sided colon cancer surgery
| Patient characteristic | Age (years) | ≤65 | 38 (66.7%) | 16 (59.3%) | 52 (45.2%) | |
| | | >65 | 19 (33.3%) | 11 (40.7%) | 63 (54.8%) | 0.007 |
| | Gender | Male | 26 (44.8%) | 13 (48.1%) | 56 (48.7%) | |
| | | Female | 32 (55.2%) | 14 (51.9%) | 59 (51.3%) | 0.641 |
| | ASA | 1 | 41 (70.7%) | 13 (48.1%) | 64 (55.7%) | |
| | | 2 | 15 (25.9%) | 13 (48.1%) | 46 (40.0%) | |
| | | 3 | 2 (3.4%) | 1 (3.7%) | 5 (4.3%) | 0.114 |
| | BMI (kg/m2) | Mean ± S.D. | 20.7 ± 3.9 | 22.4 ± 2.5 | 22.4 ± 3.3 | 0.001 |
| Operative procedure | Operation method | RHC | 45 (77.6%) | 19 (70.4%) | 75 (65.2%) | |
| | | ERHC | 13 (22.4%) | 8 (29.6%) | 40 (34.8%) | 0.096 |
| | Approach | Open | 58 (100%) | 15 (55.6%) | 34 (29.6%) | |
| | | Lap | - | 12 (44.4%) | 81 (70.4%) | <0.001 |
| | Vessel ligation | Low | 6 (26.1%) | 3 (17.6%) | 4 (3.7%) | |
| | | High | 17 (73.9%) | 14 (82.4%) | 103 (96.3%) | <0.001 |
| Macroscopic feature | Location | Cecum | 12 (20.7%) | 11 (40.7%) | 17 (14.8%) | |
| | | Ascending | 25 (43.1%) | 9 (33.3%) | 57 (49.6%) | |
| | | H flexure | 20 (34.5%) | 7 (25.9%) | 23 (20.0%) | |
| | | prox T | 1 (1.7%) | 0 | 18 (15.7%) | 0.097 |
| | Tumor size | ≤6.5 | 34 (58.6%) | 17 (63.0%) | 61 (53.5%) | |
| | | >6.5 | 24 (41.4%) | 10 (37.0%) | 53 (46.5%) | 0.467 |
| | | Mean ± S.D. | 6.5 ± 2.6 | 6.6 ± 3.2 | 6.6 ± 2.7 | 0966 |
| Microscopic feature | Stage | II | 40 (69.0%) | 18 (66.7%) | 64 (56.1%) | |
| | | III | 18 (31.0%) | 9 (33.3%) | 50 (43.9%) | 0.090 |
| | Pathologic T | 2 | 2 (3.4%) | 1 (3.7%) | 2 (1.8%) | |
| | | 3 | 47 (81.0%) | 24 (88.9%) | 100 (87.7%) | |
| | | 4 | 9 (15.5%) | 2 (7.4%) | 12(10.5%) | 0.651 |
| | Pathologic N | 0 | 36 (62.1%) | 18 (66.7%) | 64 (56.1%) | |
| | | 1 | 15 (25.9%) | 5 (18.5%) | 31 (27.2%) | |
| | | 2 | 7 (12.1%) | 4 (14.8%) | 19 (16.7%) | 0.345 |
| | Differentiation | Well | 21 (36.2%) | 16 (59.3%) | 17 (14.9%) | |
| | | Moderately | 19 (32.8%) | 6 (22.2%) | 85 (74.6%) | |
| | | Poorly | 11 (19.0%) | 3 (11.1%) | 9 (7.9%) | |
| | | Mucinous | 7 (12.1%) | 2 (7.4%) | 3 (2.6%) | 0.685 |
| | Lymphatic invasion | No | 10 (35.7%) | 15 (62.5%) | 88 (77.2%) | |
| | | Yes | 18 (64.3%) | 9 (37.5%) | 26 (22.8%) | <0.001 |
| | Venous invasion | No | 25 (89.3%) | 22 (91.7%) | 111 (97.4%) | |
| | | Yes | 3 (10.7%) | 2 (8.3%) | 3 (2.6%) | 0.051 |
| | Perineural invasion | No | 25 (86.2%) | 22 (91.7%) | 97 (85.1%) | |
| | | Yes | 4 (13.8%) | 2 (8.3%) | 17 (14.9%) | 0.708 |
| | Retrieved LN | <12 | 4 (6.9%) | 10 (37.0%) | 22 (19.3%) | |
| | | ≥12 | 54 (93.1%) | 17 (63.0%) | 92 (80.7%) | 0.103 |
| Additional treatment | Adjuvant CTx | No | 15 (26.3%) | 1 (3.8%) | 17 (14.9%) | |
| | | Yes | 42 (73.7%) | 25 (96.2%) | 97 (85.1%) | 0.105 |
| Perioperative course | OP time(mins) | Mean ± S.D. | 199.5 ± 83.4 | 308.5 ± 109.9 | 298.7 ± 86.8 | <0.001 |
| | Intraoperative Cx | No | 58 (100%) | 26 (96.3%) | 111 (96.5%) | |
| | | Yes | 0 | 1 (3.7%) | 4 (3.5%) | 0.189 |
| | Intraoperative TF (mL) | Mean ± S.D | 361.6 ± 636.4 | 120.4 ± 243.9 | 83.3 ± 224.8 | <0.001 |
| | Postoperative Cx | No | 45 (77.6%) | 22 (81.5%) | 102 (88.7%) | |
| | | Yes | 15 (22.4%) | 5 (18.5%) | 13 (11.3%) | 0.052 |
| | Postoperative TF (mL) | Mean ± S.D | 156.9 ± 362.9 | 129.6 ± 233.8 | 164.5 ± 250.7 | 0.850 |
| | Reoperation | No | 56 (96.6%) | 26 (96.3%) | 114 (99.1%) | |
| | | Yes | 2 (3.4%) | 1 (3.7%) | 1 (0.9%) | 0.223 |
| | ICU stay (days) | mean ± S.D | 4.3 ± 3.9 | 4.7 ± 3.0 | 1.9 ± 1.5 | <0.001 |
| | Hospital stay (days) | mean ± S.D | 23.5 ± 11.4 | 17.6 ± 4.2 | 13.9 ± 6.9 | <0.001 |
| Serology | Preoperative CEA (ng/mL) | ≤5 | 24 (66.7%) | 18 (72.0%) | 68 (65.4%) | |
| | | >5 | 12 (33.3%) | 7 (28.0%) | 36 (34.6%) | 0.790 |
| | Postoperative CEA(ng/mL) | ≤5 | 18 (85.7%) | 13 (92.9%) | 76 (85.4%) | |
| >5 | 3 (14.3%) | 1 (7.1%) | 13 (14.6%) | 0.818 |
ASA, American Society of Anesthesiologists; BMI, Body mass index; CEA, Carcinoembryonic antigen; CTx, Chemotherapy; Cx, Complication; ERHC, Extended right hemicolectomy; H flexure, Hepatic flexure; ICU, Intensive care unit; Lap, Laparoscopic; LN, Lymph node; prox T, Proximal transverse; RH, Right hemicolectomy; TF, Transfusion.
Figure 2 (a) The overall survival rate of stage II and III right-sided colon cancer patients in this study. ( b) Differences of overall survival rate among the three groups.
Figure 3 (a) The disease-free survival rate of stage II and III right-sided colon cancer patients in the present study. ( b) Differences of disease-free survival rate among the three groups. The disease-free survival rates of groups I and III were statistically higher than that of group II ( P = 0.042 and P = 0.050).
Univariate and multivariate analysis for overall survival and disease-free survival in this study
| | | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | I | 86.1 | 82.5 | 61.1 | | | 87.5 | 85.6 | 81.2 | | |
| | II | 70.3 | 66.7 | 59.3 | | | 66.7 | 62.9 | 62.9 | | |
| | III | 77.2 | 71.2 | 64.9 | 0.655 | NS | 82.8 | 81.5 | 81.5 | 0.102 | NS |
| Location | Cecum | 82.1 | 79.5 | 63.4 | | | 84.6 | 78.6 | 78.6 | | |
| | Ascending | 79.1 | 71.9 | 57.8 | | | 81.8 | 80.3 | 73.9 | | |
| | Hepatic flexure | 77.9 | 75.6 | 59.4 | | | 81.3 | 81.3 | 81.3 | | |
| | Proximal transverse | 73.7 | 66.9 | 58.6 | 0.736 | NS | 78.6 | 78.6 | 78.6 | 0.968 | NS |
| Approach | Open | 78.3 | 73.4 | 57.5 | | | 81.6 | 78.4 | 75.3 | | |
| | Lap | 79.4 | 74.8 | 66.3 | 0.884 | | 82.2 | 82.2 | 82.2 | 0.518 | NS§ |
| Vessel ligation | Low ligation | 76.9 | 69.2 | 55.4 | | | 69.2 | 69.2 | 69.2 | | |
| | High ligation | 78.9 | 74.1 | 63.8 | 0.834 | NS | 83.1 | 83.1 | 83.1 | 0.185 | NS |
| Stage | II | 87.6 | 81.8 | 66.6 | | | 89.1 | 87.9 | 83.9 | | |
| | III | 64.8 | 61.6 | 45.5 | 0.004 | NS | 69.9 | 66.2 | 66.2 | <0.001 | NS |
| Pathologic T | 2 | 60.0 | 60.0 | 60.0 | | | 60.0 | 60.0 | 60.0 | | |
| | 3 | 82.4 | 78.2 | 62.3 | | | 84.3 | 82.6 | 80.5 | | |
| | 4 | 56.2 | 45.4 | 31.1 | 0.003 | NS | 67.3 | 60.6 | 52.9 | 0.015 | NS |
| Pathologic N | 0 | 87.3 | 81.3 | 66.9 | | | 89.6 | 88.3 | 84.1 | | |
| | 1 | 72.4 | 70.1 | 48.2 | | | 80.9 | 80.9 | 80.9 | | |
| | 2 | 55.2 | 50.6 | 43.4 | 0.008 | NS | 53.1 | 44.6 | 44.6 | <0.001 | NS |
| Differentiation | Well | 85.2 | 79.5 | 68.5 | | | 88.4 | 84.4 | 80.7 | | |
| | Moderately | 79.9 | 75.1 | 50.8 | | | 83.3 | 83.3 | 83.3 | | |
| | Poorly | 60.9 | 56.2 | 45.4 | | | 65.9 | 59.9 | 53.9 | | |
| | Mucinous | 72.7 | 72.7 | 60.6 | 0.091 | NS | 66.7 | 66.7 | 66.7 | 0.025 | NS |
| Lymphatic invasion | No | 83.9 | 79.6 | 63.6 | | | 87.4 | 87.4 | 87.4 | | |
| | Yes | 64.2 | 59.7 | 45.3 | 0.004 | 0.005 | 65.4 | 63.2 | 63.2 | <0.001 | <0.001 |
| Venous invasion | No | 79.7 | 75.1 | 58.4 | | | 83.6 | 82.8 | 82.8 | | |
| | Yes | 25.0 | 25.0 | 25.0 | <0.001 | 0.001 | 12.5 | 12.5 | 12.5 | <0.001 | <0.001 |
| Perineural invasion | No | 80.5 | 77.1 | 59.1 | | | 82.9 | 82.9 | 82.9 | | |
| | Yes | 56.5 | 46.3 | 46.3 | 0.029 | NS | 62.2 | 55.9 | 55.9 | 0.006 | NS |
| Lymph node retrieval | <12 | 58.3 | 52.5 | 45.9 | | | 62.8 | 62.8 | 62.8 | | |
| | ≥12 | 83.3 | 78.8 | 62.3 | 0.012 | 0.031 | 85.9 | 83.4 | 80.5 | 0.002 | <0.001 |
| Adjuvant CTx | No | 69.7 | 62.1 | 36.5 | | | 82.6 | 82.6 | 82.6 | | |
| | Yes | 80.3 | 76.1 | 65.1 | 0.008 | NS | 81.4 | 79.0 | 75.9 | 0.621 | NS |
| Reoperation | No | 79.4 | 74.5 | 60.1 | | | 82.1 | 79.9 | 77.4 | | |
| | Yes | 50.0 | 50.0 | 25.0 | 0.041 | NS | 75.0 | 75.0 | 75.0 | 0.463 | NS |
| Preoperative CEA | ≤5 | 89.1 | 83.5 | 68.1 | | | 89.8 | 87.5 | 82.3 | | |
| | >5 | 64.7 | 62.5 | 49.1 | 0.003 | 0.031 | 68.2 | 65.2 | 65.2 | <0.001 | <0.001 |
| Postoperative CEA | ≤5 | 83.1 | 77.8 | 65.1 | | | 82.8 | 80.0 | 75.8 | | |
| >5 | 52.9 | 52.9 | 52.9 | 0.018 | NS | 64.2 | 64.2 | 64.2 | 0.051 | NS | |
CEA, Carcinoembryonic antigen; CTx, Chemotherapy; NS, Not significant.
Figure 4 These graphs show the difference of overall survival (OS) and disease-free survival (DFS) between the open surgery group and the laparoscopic surgery group according to the time sequence. ( a) and ( b) are graphs for OS and DFS, respectively, in group II; ( c) and ( d) in group III.
Analysis for risk factor of local recurrence in this study
| Group | I | 51 (87.9%) | 7 (12.1%) | | |
| | II | 25 (92.6%) | 2 (7.4%) | | |
| | III | 112 (97.4%) | 3 (2.6%) | 0.013 | 0.304 |
| Location | Cecum | 36 (90.0%) | 4 (10.0%) | | |
| | Ascending | 87 (95.6%) | 4 (4.4%) | | |
| | Hepatic flexure | 47 (94.0%) | 3 (6.0%) | | |
| | Proximal transverse | 18 (94.7%) | 1 (5.3%) | 0.525 | |
| Approach | Open | 98 (91.6%) | 9 (8.4%) | | |
| | Lap | 90 (96.8% | 3 (3.2%) | 0.146 | |
| Vessel ligation | Low ligation | 11 (84.6%) | 2 (15.4%) | | |
| | High ligation | 130 (97%) | 4 (3.0%) | 0.032 | 0.019 |
| Stage | II | 117 (95.9%) | 5 (4.1%) | | |
| | III | 70 (90.9%) | 7 (9.1%) | 0.220 | |
| Pathologic T | 2 | 5 (100%) | 0 | | |
| | 3 | 162 (94.7%) | 9 (5.3%) | | |
| | 4 | 20 (87.0%) | 3 (13.0%) | 0.118 | |
| Pathologic N | 0 | 113 (95.8%) | 5 (4.2%) | | |
| | 1 | 46 (90.2%) | 5 (9.8%) | | |
| | 2 | 28 (93.3%) | 2 (6.7%) | 0.355 | |
| Differentiation | Well | 53 (98.1%) | 1 (1.9%) | | |
| | Moderately | 104 (94.5%) | 6 (5.5%) | | |
| | Poorly | 19 (82.6%) | 4 (17.4%) | | |
| | Mucinous | 11 (91.7%) | 1 (8.3%) | 0.042 | 0.571 |
| Lymphatic invasion | No | 108 (95.6%) | 5 (4.4%) | | |
| | Yes | 50 (94.3%) | 3 (5.7%) | 0.711 | |
| Venous invasion | No | 152 (96.2%) | 6 (3.8%) | | |
| | Yes | 6 (75.0%) | 2 (25.0%) | 0.049 | 0.643 |
| Perineural invasion | No | 137 (95.1%) | 7 (4.9%) | | |
| | Yes | 22 (95.7%) | 1 (4.3%) | 0.915 | |
| Lymph node retrieval | <12 | 31 (86.1%) | 5 (13.9%) | | |
| | ≥12 | 156 (95.7%) | 7 (4.3%) | 0.044 | 0.995 |
| Adjuvant CTx | No | 31 (93.9%) | 2 (6.1%) | | |
| | Yes | 154 (93.9%) | 10 (6.1%) | 0.994 | |
| Reoperation | No | 184 (93.9%) | 12 (6.1%) | | |
| | Yes | 4 (100%) | 0 | 0.611 | |
| Preoperative CEA | ≤5 | 105 (95.5%) | 5 (2.5%) | | |
| | >5 | 51 (92.7%) | 4 (7.3%) | 0.483 | |
| Postoperative CEA | ≤5 | 102 (95.3%) | 5 (4.7%) | | |
| >5 | 16 (94.1%) | 1 (5.9%) | 0.595 |
CEA, Carcinoembryonic antigen; CTx, Chemotherapy.